Several R&D Activities Coupled with the Increasing Number of Patients with Acute Heart Failures due to Unhealthy Lifestyle is Expected to Propel the Growth of The Global Neprilysin Market.

Published: Apr 2022

The global neprilysin market is anticipated to grow at a considerable CAGR during the forecast years. Neprilysin is a zinc-dependent metalloprotease used in the neprilysin inhibitors for the treatment of high blood pressure and heart failures. Acute heart failure is a chronic medical condition in which the heart doesn’t pump the blood as it is required. The reason for the growth of the market is there increasing the number of patients suffering from acute heart failure which is increasing the demand for the neprilysin for treatment. According to a report published on Wiley Online Library in June 2020, an estimated around 64.3 million people worldwide are living with acute heart failure. These numbers are expected to increase in the coming years. Due to the unhealthy lifestyle and eating habits of people, the number of acute heart failure patients is increasing across the globe. Thus, increasing the demand for neprilysin inhibitors for the treatment.

Browse the full report description “Global Neprilysin Market Size, Share & Trend Analysis Report by Type (TD-0714, Sacubitril, PL-265, STR-324, and LHW-090), by Application (Acute Heart Failure, Cancer Pain, Hypertension, and Alzheimer’s disease), Forecast (2022-2028)” at https://www.omrglobal.com/industry-reports/neprilysin-market

In addition, there are several research and developments intended for the betterment of neprilysin inhibitors for the better treatment of acute heart failures and hypertension. According to a study published on ACP Internist in December 2021, the combination of angiotensin receptor and neprilysin inhibitors proved to be more beneficial in patients with acute heart failures. Furthermore, as per the report published by MDPI in August 2021, the report concludes that the combination of sacubitril and valsartan is the potent pharmacological agent to treat several cardiovascular diseases including acute heart failures. The several research and development coupled with the increasing number of acute heart failure patients, that is increasing the demand for neprilysin is expected to propel the growth of the global neprilysin market.

Market Coverage

  • The market number available for – 2022-2028
  • Base year- 2021
  • Forecast period- 2022-2028

Segment Covered- 

  • By Type
  • By Application

Regions Covered-

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape- Merck Group, GlaxoSmithKline plc, Cipla Ltd., Novartis International AG, Pharmaleads SA, and Others.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How are players addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Neprilysin Market Report Segment

By Type

  • TD-0714
  • Sacubitril
  • PL-265
  • STR-324
  • LHW-090

By Application

  • Acute Heart Failure
  • Cancer Pain
  • Hypertension
  • Alzheimer’s Disease

Global Neprilysin Market Report Segment by Region

North America

  • The US
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific 

Rest of the World

  • Latin America 
  • Middle East & Africa


To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/neprilysin-market